• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Alcon Inc.: PharmaVitae Profile Product Image

Alcon Inc.: PharmaVitae Profile

  • Published: December 2010
  • Region: World
  • 102 Pages
  • Datamonitor

Introduction

This analysis examines the historical and forecast performance for Alcon in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

- Gain insight into Alcon's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

- Strategic insight into the prospects for Alcon over the next six years.
- Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

- Benchmark Alcon's performance against key rivals in the prescription pharmaceutical sector
- Assess the implications of Novartis's ~$50 billion acquisition of Alcon
- Alcon's eye care portfolio has delivered impressive historical revenue growth, with margin expansion lifting profits further, but can this continue?

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–
Financial performance, 2003–
Alcon: PharmaVitae forecasts at a glance
Strategic insight
[Missing title]
Ophthalmology focus may restrict opportunity
Potential consolidation with Novartis would allow further synergies
SWOT analysis
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Key findings
Latest prescription pharma product news
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Current corporate structure
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–
Product analysis
Product analysis, 2003–
Product analysis, 2009–
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-
Core analysis, 2009-
Expiry analysis, 2009-
Generics analysis, 2009-
Launch/core/expiry configuration, 2009–
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–
Operating costs and profit analysis
Operating costs and profit analysis, 2003–
Operating cost ratio and profit margin analysis, 2003–
Operating cost ratio and profit margin analysis, 2009–
Operating costs and profit analysis, 2009–
KEY PRODUCTS
Key findings
Travatan franchise
Azopt
Patanol franchise
Vigamox
Ciprodex
Patanase
APPENDIX
R&D pipeline
Therapy area by company reporting line
References
Abbreviations
Exchange rates

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS